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Objectives
European guidelines recommend HIV testing for individuals presenting with indicator conditions
(ICs) including AIDS-defining conditions (ADCs). The extent to which non-HIV specialty guidelines
recommend HIV testing in ICs and ADCs is unknown. Our aim was to pilot a methodology in the
UK to review specialty guidelines and ascertain if HIV was discussed and testing recommended.
Methods
UK and European HIV testing guidelines were reviewed to produce a list of 25 ADCs and 49 ICs.
UK guidelines for these conditions were identified from searches of the websites of specialist
societies, the National Institute of Clinical Excellence (NICE) website, the NICE Clinical Knowledge
Summaries (CKS) website, the Scottish Intercollegiate Guidance Network (SIGN) website and the
British Medical Journal Best Practice database and from Google searches.
Results
We identified guidelines for 12 of 25 ADCs (48%) and 36 of 49 (73%) ICs. In total, 78 guidelines
were reviewed (range 0–13 per condition). HIV testing was recommended in six of 17 ADC
guidelines (35%) and 24 of 61 IC guidelines (39%). At least one guideline recommended HIV
testing for six of 25 ADCs (24%) and 16 of 49 ICs (33%). There was no association between
recommendation to test and publication year (P = 0.62).
Conclusions
The majority of guidelines for ICs do not recommend testing. Clinicians managing ICs may be
unaware of recommendations produced by HIV societies or the prevalence of undiagnosed HIV
infection among these patients. We are piloting methods to engage with guideline development
groups to ensure that patients diagnosed with ICs/ADCs are tested for HIV. We then plan to apply
our methodology in other European settings as part of the Optimising Testing and Linkage to Care
for HIV across Europe (OptTEST) project.
Keywords: AIDS-defining conditions, HIV testing, indicator conditions
Accepted 2 June 2016
Introduction
Despite extensive efforts to promote HIV testing, late
diagnosis (CD4 count at diagnosis < 350 cells/lL) [1]
continues to be reported in almost half of all newly diag-
nosed cases in Europe, and 27% of patients diagnosed
with HIV infection present with advanced HIV disease
(CD4 count < 200 cells/lL) [2]. Rates of late diagnosis do
not appear to be improving. A meta-regression of
Correspondence: Dr Emily Lord, Department of Sexual Health, The
Churchill Hospital, Oxford University Hospitals NHS Trust, Old Road,
Headington, Oxford, OX3 7LE, United Kingdom. Tel: +44 1865 231231;
fax: 01865 234452; e-mail: Emilylord81@gmail.com
*Joint first authors.
†See Appendix.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
300
DOI: 10.1111/hiv.12430
© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2017), 18, 300--304
SHORT COMMUNICATION
temporal trends in studies reporting CD4 count at diagno-
sis in Europe and North America showed no significant
increase over a 20-year period between 1992 and 2011
[3]. Data from European HIV-infected cohorts have
demonstrated no change in median CD4 count at presen-
tation among 30 454 patients from 34 countries between
2010 and 2013 [adjusted change per year 1.2 cells/lL;
95% confidence interval (CI) 0.8 to 3.3 cells/lL] [4].
The importance of early diagnosis is clear: almost all
HIV-associated mortality is attributable to late diagnosis,
with a 1-year relative risk of mortality between 6.6 and
13 in the first year for late diagnoses, depending on
European region [1]. Diagnosis at a CD4 count of
100–199 or < 100 cells/lL was associated with a mean
of 17.8 and 20.9 years of life lost, respectively, in the
UK collaborative HIV-infected cohort, compared with
those diagnosed at > 350 cells/lL [5]. Initiation of
antiretroviral therapy (ART) at a CD4 count > 500 cells/
lL is associated with a reduced risk of malignancy, car-
diovascular disease and infection [6]. Late initiation of
ART is associated with poorer treatment responses, as
well as persistence of metabolic and inflammatory
abnormalities even after years of treatment [7,8]. Addi-
tionally, earlier diagnosis presents an opportunity to pre-
vent onward transmission.
The HIV Indicator Diseases Across Europe Study
(HIDES 1) recruited patients from 200 health care cen-
tres in Europe and offered HIV testing to patients pre-
senting with one of eight indicator conditions (ICs) in
order to ascertain the prevalence of undiagnosed HIV
infection. Across all eight ICs, the prevalence of HIV
infection was 1.8% (95% CI 1.42.3%) and ranged from
0.29 to 4.1%; all eight conditions were associated with
a prevalence exceeding 0.1% [9]. In a subsequent study,
HIDES 2, HIV prevalence exceeded a predetermined
cost-effectiveness threshold of 0.1% among patients pre-
senting with 10 of 14 indicator conditions [10]. Despite
this accumulating evidence, a gap persists between
European and national guidelines for testing and imple-
mentation, resulting in missed opportunities for diagno-
sis [11].
European guidelines recommend HIV testing for indi-
viduals presenting with AIDS-defining conditions (ADCs)
and ICs (defined as those associated with an undiagnosed
HIV prevalence of > 0.1%, or conditions where failure to
identify HIV infection may have both health and treat-
ment implications [12]). Guidelines from HIV societies
inform those working in the HIV community, yet it is
other medical specialties that see the majority of patients
presenting with ADCs and ICs. It is therefore important to
ensure that non-HIV specialist guidelines for the manage-
ment of these conditions appropriately recommend HIV
testing. Currently, the extent to which such recommenda-
tions occur is unknown.
Our aim was to determine the proportion of UK guide-
lines for ADCs and ICs that appropriately recommend
HIV testing and to develop methodology that could be
applied to other European countries as part of the Opti-
mising Testing and Linkage to Care for HIV across Europe
(OptTEST) project (www.OptTEST.eu). Ultimately, the aim
is to identify opportunities to facilitate inclusion of HIV
testing recommendations in future guidelines.
Methods
European (2012) [12] and UK HIV testing guidelines
(2008) [13] were reviewed to develop the list of 25 ADCs
and 49 ICs [12,13] (Table S1). We conducted a literature
search for relevant UK specialty guidelines for each ADC
and IC, including relevant specialty society, association
or college websites, the National Institute of Clinical
Excellence (NICE) website, the NICE Clinical Knowledge
Summaries (CKS) (which provide guidelines for primary
care physicians) website, the Scottish Intercollegiate
Guidance Network (SIGN) website, the British Medical
Journal Best Practice database and Google. HIV-specific
guidelines and those published by the British Association
of Sexual Health and HIV (BASHH) were excluded. For
example search strategies, please see the Appendix S1.
Each guideline was reviewed and classified into one of
three categories: (1) HIV was not mentioned in the guide-
line; (2) the association with HIV was mentioned but test-
ing was not recommended; (3) HIV was mentioned and
testing recommended.
The associations of recommendation to test with cate-
gorical variables (source of guideline and type of condi-
tion) and with year of publication were tested using
Fisher’s exact test and MantelHaenszel linear-by-linear
chi square tests, respectively. Data from guidelines were
tabulated in a Microsoft Excel database (Microsoft, Red-
mond, WA, USA). Statistical analyses were conducted
using SPSS version 22 (IBM, Armonk, NY, USA).
Results
A total of 78 relevant guidelines were identified (range
1–13 per condition); 17 for ADCs (range 0–4) and 61 for
ICs (range 0–13) (Table 1). Guidelines were identified for
12 of 25 ADCs (48%) and 36 of 49 ICs (73%) (Table S1).
Association with HIV was discussed in nine of 17
(53%) ADC guidelines and 32 of 61 IC guidelines (52%),
whereas HIV testing was appropriately recommended in
six of 17 ADC guidelines (35%) and 24 of 61 IC guideli-
nes (39%) (Table 1). At least one guideline recommended
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HIV testing for six of 25 ADCs (24%) and 16 of 49 ICs
(33%). National guidelines from NICE, including clinical
knowledge summaries, or from SIGN were less likely to
recommend HIV testing than specialist society guidelines
(29 vs. 55%, respectively; P = 0.02). Guidelines for the
eight key ICs identified in the HIDES 1 study were sig-
nificantly more likely to recommend HIV testing than
those for remaining ICs (59 vs. 23%, respectively;
P = 0.002). No association was observed between year
of publication and recommendation to test (P = 0.620);
see Figure 1.
Discussion
Only 38% of the guidelines for ADCs and ICs that we
identified from UK guidelines recommended HIV testing.
While over half of guidelines (53%) acknowledged an
association between HIV and the condition, over a quar-
ter of these did not go on to recommend HIV testing. We
further identified that the national guideline development
bodies NICE and SIGN were significantly less likely to
recommend testing compared with specialist society
guidelines. The underlying cause of this is unclear. It is
important that HIV physicians and National Boards of
Health at both European and national levels take the
opportunity to engage with guideline development groups
to promote testing.
It has been reported that a significant proportion of
undiagnosed patients present to health care providers
with a clinical episode directly related to HIV [14].
Table 1 Recommendation for HIV testing and reporting of association with HIV, stratified by type of guideline
Number of
guidelines
identified
(%
of total)
Association
with HIV
reported
n (%)
HIV testing
recommended
n (%)
P-value for
between-group
difference in
HIV testing
recommendation
All guidelines 78 (100) 41 (53) 30 (38)
AIDS-defining conditions 17 (21) 9 (53) 6 (35) 1.0
Indicator conditions 61 (78) 32 (52) 24 (39)
Source of guideline
NICE 12 (15) 7 (58) 3 (25) 0.021
NICE Clinical Knowledge Summaries 29 (37) 18 (62) 11 (38)
SIGN 8 (10) 0 (0) 0 (0)
Specialty society guidelines 29 (37) 16 (55) 16 (55)
Guidelines for eight key indicator conditions*
Total 34 (100) 27 (79) 20 (59) 0.002†
Sexually transmitted infections 13 (38) 13 (100) 7 (54) 0.20
Malignancy or lymphoma 3 (9) 3 (100) 3 (100)
Cervical or anal cancer/dysplasia 5 (15) 1 (20) 1 (20)
Herpes zoster 1 (3) 0 (0) 0 (0)
Hepatitis B or C virus (acute or chronic) 6 (18) 4 (67) 4 (67)
Mononucleosis-like illness 2 (6) 2 (100) 1 (50)
Unexplained leucocytopaenia, thrombocytopaenia (>4 weeks) 3 (9) 3 (100) 3 (100)
Seborrhoeic dermatitis/exanthema 1 (3) 1 (100) 1 (100)
NICE, National Institute of Clinical Excellence; SIGN, Scottish Intercollegiate Guidance Network.
*The eight key indicator conditions were tested as part of the HIDES 1 study and were associated with a prevalence of undiagnosed HIV infection of
>0.1%.
†The P-value refers to the comparison between guidelines for the eight key indicator conditions and remaining guidelines.
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Fig. 1 Recommendation for HIV testing in AIDS-defining conditions
(ADCs) and indicator conditions (ICs), stratified by year of guideline
publication: no association was observed between publication year
and recommendation to test (P = 0.620). ADCs are indicated by
cross-hatched boxes.
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Additionally, individuals newly diagnosed with HIV
infection report a high level of prior attendance in pri-
mary and secondary care where opportunities for earlier
diagnosis were missed [15]. In a cross-sectional analysis
from a multicentre data set from general practice, 59% of
patients diagnosed with HIV infection had exhibited an
indicator condition in the 5 years prior to diagnosis com-
pared with 7% among matched controls [16]. A lack of
awareness surrounding ICs and lack of confidence in
offering testing are common barriers among physicians
to offering a test [12]. Reassuringly, evidence suggests
that, despite low offer rates, when an HIV test is sug-
gested, uptake approaches 100% [17]. This highlights that
the key barrier to HIV testing is that the test is not
offered, rather than patients refusing.
Review of guidelines for the eight key indicator condi-
tions included in the HIDES 1 study indicates that a
higher proportion did recommend testing. However, sev-
eral key guidelines failed to do so. Only 54% of sexually
transmitted infection (STI) guidelines (all published by
NICE) recommend HIV testing (http://cks.nice.org.uk).
While it may have been suggested to screen for other
STIs, 46% of guidelines failed to explicitly advise that
this should include HIV and, while patients attending
sexual health clinics are usually routinely screened for
HIV, those who present to their GPs may not. Given the
increased risk of transmission associated with concomi-
tant STIs, it is particularly important that such guidelines
reinforce the need for testing [18]. Additionally, patients
infected with HIV have a higher incidence of both cervi-
cal and anal dysplasia, with increased rates of progres-
sion to cancer without treatment [19]. However, only
20% of guidelines on cervical and anal dysplasia recom-
mended HIV testing. Mononucleosis-like illnesses can
mimic HIV seroconversion, which occurs in up to 80% of
patients who acquire HIV [20]. However, only one of the
two guidelines identified recommended testing. Patients
may present with these symptoms to their GP, and during
this highly infectious period a prompt diagnosis is essen-
tial. In HIDES 2, 5.3% of patients with suspected
mononucleosis tested positive for HIV [10]. Patients with
ICs may already have late-stage HIV infection, and failure
to test for HIV may have an adverse impact on long-term
prognosis [5]. With clear evidence that testing in these
situations is cost effective [17], it raises the question as to
why testing is not recommended in all relevant evidence-
based guidelines.
Limitations to this project include the lack of estab-
lished methodology for searching for national guidelines,
particularly in comparison to methods for searching
biomedical literature; many guidelines are not indexed
on biomedical databases. There was also a degree of
subjectivity to determination of a testing recommenda-
tion; in some cases guidance was ambiguous and this
wording should be clarified.
IC-guided HIV testing is an acceptable, feasible and
important part of the strategy to disrupt HIV transmission
and promote earlier diagnosis in Europe. Specialists
managing ICs may be unaware of national recommenda-
tions produced by HIV societies, the prevalence of undi-
agnosed HIV infection among patient with ICs and the
cost of missing opportunities to make an early diagnosis.
It is intended that this guideline review process will be
extended to other European countries. We are currently
developing methods of engaging with guideline develop-
ment groups to ensure that HIV testing is recommended
in future guideline revisions.
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